Metraipolis › archive › dc_f0357be51db2
Novel target identification towards drug repurposing based on biological activity profiles — Europe PMC PMID:40327632
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40327632
- DOI
- 10.1371/journal.pone.0319865
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T11:29:25.733Z
- SHA-256 of the archived text
08323a13adc86d089d0ca56d9911b844a804ed75a5091ff1d8360d8bfea85c09- Stable URL of this page
https://metraipolis.com/documento/dc_f0357be51db2
How to cite
Novel target identification towards drug repurposing based on biological activity profiles — Europe PMC PMID:40327632 — Europe PMC (en), https://europepmc.org/article/MED/40327632 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f0357be51db2 (Metraipolis archive dc_f0357be51db2, sha256 08323a13adc86d089d0ca56d9911b844a804ed75a5091ff1d8360d8bfea85c09)
BibTeX
@misc{dcf0357be51db2,
title = {Novel target identification towards drug repurposing based on biological activity profiles — Europe PMC PMID:40327632},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40327632},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f0357be51db2; sha256 08323a13adc86d089d0ca56d9911b844a804ed75a5091ff1d8360d8bfea85c09},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40327632. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Rare diseases affect more than 30 million individuals, with the majority facing limited treatment options, elevating the urgency to innovative therapeutic solutions. Addressing these medical challenges necessitates an exploration of novel treatment modalities. Among these, drug repurposing emerges as a promising avenue, offering both potential and risk mitigation. To achieve this goal, we primarily focused on developing predictive models that harness cutting-edge computational techniques to uncover latent relationships between gene targets and chemical compounds towards drug repurposing. Building upon our previous investigation, where we successfully identified gene targets for compounds from the Tox21 in vitro assays, our endeavor expanded to a systematic prediction of potential targets for drug repurposing employing machine learning models built on diverse algorithms such as Support Vector Classifier, K-Nearest Neighbors, Random Forest, and Extreme Gradient Boosting. These models were trained on comprehensive biological activity profile data to predict the relationship between 143 gene targets and over 6000 compounds. Our models demonstrated high accuracy (>0.75), with predictions further validated by using public experimental datasets. Furthermore, several findings were evaluated via case studies. By elucidating these connections, we aim to streamline the drug repurposing process, ultimately catalyzing the discovery of more effective therapeutic interventions for rare diseases. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-05-06). Identificativi: PMID 40327632 · PMCID PMC12054903 · DOI 10.1371/journal.pone.0319865. Descrittori MeSH principali: Drug Repositioning. Pagina: https://europepmc.org/article/MED/40327632 — https://doi.org/10.1371/journal.pone.0319865. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T09:52:29.988Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.